

Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression"

Alireza Mirzaee¹

¹ Shiraz University

Potential competing interests: No potential competing interests to declare.

The manuscript presents an innovative treatment approach for early type 1 diabetes, amalgamating a dual GLP-1 agonist with degludec basal insulin. I appreciate the study's potential breakthrough in diabetes management but underscore some noteworthy concerns. While acknowledging the relevance of the research, it is necessary to express a collective desire for enhanced clarity, logical coherence, and a more focused exploration of the central topic. Divergence from the primary focus and the introduction of concepts seemingly unrelated to the core research generate apprehension. There's a consistent call for a more concentrated discussion on the inherent challenges of type 1 diabetes treatment. The need for robust evidence, comprehensive referencing, and detailed participant information, including the measurement of anti-GAD antibodies and participant sex, is uniformly emphasized. It is recommended to present the proposal of mechanisms, such as the reversal of the autoimmune response, but advocate for deeper, evidenced exploration. The intriguing notion of reprogramming liver cells into insulin-producing cells raises curiosity but necessitates further clarification amid ongoing debates. The suggestion for expanded literature exploration, particularly in the historical context, is deemed constructive. Despite these critiques, the manuscript is recognized for its potential to reshape type 1 diabetes treatment.